Cannabis edibles with CBD and THC relieve pain and improve cognitive function in cancer patients

Cannabis edibles with CBD and THC alleviate pain and improve cognitive functions in oncology patients. This thesis gained empirical support in a naturalistic study by Angela Bryan, Gregory Giordano, and Laurie Bidwell from the University of Colorado Boulder (Exploration of Medicine, 2023/2024). In a two-week observation of 25 oncology patients purchasing edible products in legal recreational pharmacies in Colorado, the team demonstrated a sharp decrease in pain 2 hours after dosing and an objective improvement in reaction time and working memory after 14 days of use. Our guide breaks down the study protocol, pharmacokinetics of edibles, compares results with works by Tramer 2001, Abrams 2020, and CanCord 2020, and provides Polish safety frameworks for palliative care.

The article was prepared by Michał Waluk based on peer-reviewed medical publications (Bidwell et al. 2023/2024, Exploration of Medicine; Tramer 2001 BMJ; Abrams 2020 Cancer; CanCord Good 2020 Journal of Palliative Medicine; JACC CardioOncology 2024; American Society of Clinical Oncology; National Cancer Institute; PubMed Central).

What did the study by Bidwell et al. reveal about cannabis edibles in oncology patients?

The study by Bidwell et al. from the University of Colorado Boulder (Exploration of Medicine, 2023/2024) included 25 patients diagnosed with cancer. After 14 days of using edibles ad libitum, acute pain 2 hours post-dose decreased by about 43 percent on the NRS scale, and objective reaction time in the DSST test improved in most participants, which the authors interpreted as a lack of long-term cognitive impairment.

The Boulder team conducted a so-called mobile laboratory design. Patients reported for a baseline visit, during which NRS pain, sleep quality in the Pittsburgh Sleep Quality Index, neuropsychiatric symptoms, and a series of cognitive tests were measured. They then purchased their chosen edible product from a legal recreational pharmacy in Colorado. After two weeks of self-administration, the mobile laboratory would come to the patient's home and repeat measurements before and 2 hours after dosing.

Results were analyzed in two ways. The acute effect, comparing baseline and 2 hours post-dose during the final visit, showed a clear decrease in pain, a reduction in anxiety distress symptoms, and a subjective sense of relaxation. The two-week effect, measured by the change between the baseline visit and the final visit before dosing, showed improvement in continuous pain, sleep quality, and some cognitive functions. This second finding was the most discussed in the media, as it challenges the classic assumption of persistent cognitive impairment with long-term THC use.

cannabis pain treatment in oncology, a pillar article on CBD in chronic pain

What edibles did the participants choose?

The protocol allowed for complete freedom of purchase. Participants chose gummies, chocolates, baked goods, sublingual tinctures, capsules, and ready-made cannabinoid beverages. The authors recorded three main chemical profiles: high-THC products, balanced 1:1 THC to CBD products, and high-CBD products with minimal THC. The average single dose of THC ranged from 5 to 25 milligrams, and CBD from 10 to 50 milligrams. Dosing was self-directed and based on the patient's previous experience or budtender recommendations.

In Polish conditions, such an experiment is impossible. An oncology patient has access to medical marijuana from a pharmacy only with an RPW prescription and to legal CBD products without a prescription. Therefore, the results of Bidwell should be read as a signal, not a direct clinical instruction for Polish patients. In daily conversations with store customers, we observe that the biggest issue remains access to a standardized dose, rather than the availability of the product itself.

What were the objective measurements?

The team used DSST tests (Digit Symbol Substitution Test), Trail Making Test B, Stroop Test, and working memory tests. The average improvement in DSST was about 8 to 12 percent between the baseline visit and the final visit before dosing. The researchers interpreted this as a secondary effect, meaning that pain reduction and improved sleep translate into better cognition, rather than a direct action of cannabinoids.

How do edibles pharmacokinetically differ from inhalation?

Edibles undergo the so-called first-pass hepatic effect, in which THC is metabolized to 11-hydroxy-THC. According to a review in the Journal of Analytical Toxicology (Huestis 2007, 2019) 11-OH-THC is about 2-3 times more psychoactive than THC and is significantly longer active. For the oncology patient, this means longer analgesic and antiemetic effects, but also a slower onset (30-120 minutes) and a higher risk of overdose.

The comparison with inhalation is crucial for palliative care. Vaporization or smoking gives a peak plasma concentration in 5-10 minutes and an effect lasting 2-4 hours. Edibles start after 30-120 minutes and work for 4-8 hours, sometimes up to 12 hours in a CBD-dominant model. In the context of nighttime cancer pain or chronic nausea after chemotherapy, the longer action is an advantage as it reduces the number of daily doses and stabilizes relief overnight.

The problem is that inexperienced patients often do not wait for the effect and take a second dose after 45 minutes. This leads to so-called edibles overdose, which manifests as panic, tachycardia, vomiting, and fainting, but is not fatal in terms of respiratory function, unlike opioids. ASCO and NCI (National Cancer Institute PDQ Cannabis) recommend the principle of start low, go slow, meaning 2.5 to 5 mg of THC for the first dose and a full 2 hours of observation.

Why does 11-OH-THC change the risk profile?

The metabolite 11-OH-THC better crosses the blood-brain barrier and more strongly stimulates CB1 receptors. In the geriatric literature (PMC Minerva 2018) increased fall risk in seniors aged 65 and older after edible marijuana, especially in the first 3 hours post-dose. For an oncology patient with steroid-induced osteopenia or polychemotherapy neuropathy, the risk of a proximal femur fracture is real, hence it is recommended to take edibles while sitting or lying down and to avoid driving for 12 hours.

How does this relate to drug interactions?

CBD and THC pass through cytochromes CYP3A4, CYP2C9, CYP2C19, and the P-glycoprotein transporter. Cytostatics such as paclitaxel, vincristine, cyclophosphamide, doxorubicin, and the tyrosine kinase inhibitor imatinib are substrates of the same enzymes. One study in JACC CardioOncology (2024) described cases of atypical toxicity profiles in patients combining medical marijuana with doxorubicin, explained by P-gp inhibition. Always verify the medication list with a clinical pharmacist or oncologist before starting edibles.

How do Bidwell's results compare with classic oncological literature?

A meta-analysis by Tramer et al. in the British Medical Journal (BMJ, 2001) encompassing 30 randomized studies and 1366 patients showed that oral dronabinol and nabilone were statistically more effective than neuroleptics in controlling nausea and vomiting after chemotherapy (CINV), but were inferior to modern setrons. Bidwell adds two new elements to this picture: naturalistic retail edibles and a cognitive component.

The classic oncological evidence base focused on CINV and cachexia. Tramer 2001 is a reference point. Then Abrams et al. in the journal Cancer (Abrams 2020) described the safety and tolerance of oral THC to CBD 1:1 in CINV prevention in small cohorts. CanCord Good et al. in the Journal of Palliative Medicine (Good 2020) conducted a randomized study with cannabidiol in palliative care, showing no significant improvement in overall quality of life but signaling pain improvement in a subgroup of patients.

Bidwell methodologically differs from these studies in three points. First, it studies retail edibles, not a defined product. Second, it takes self-selected doses. Third, it introduces objective cognitive tests, not just self-assessment. This explains why the results align more closely with real patient practice in Colorado, while simultaneously complicating replication in RCT.

What does the American Society ASCO say?

The American Society of Clinical Oncology in its 2023 position emphasizes that evidence for the anti-cancer effects of cannabinoids is preclinical and does not justify cannabis monotherapy in humans. ASCO allows medical marijuana as an adjunct therapy in controlling cancer pain, CINV resistant to setrons, appetite loss, and sleep disorders, but only within a documented shared decision-making framework with the attending oncologist.

Why did Good 2020 not show a global improvement in quality of life?

CanCord Good 2020 used pure CBD at doses of 50-600 mg daily over a period of 28 days. The absence of THC may explain the lack of entourage effect synergy observed with full-spectrum products. Bidwell likely captured this synergy, as patients predominantly chose edibles with THC. In the literature, this difference is known as the cannabinoid-terpene entourage effect.

What are the limitations of Bidwell's naturalistic protocol?

The Bidwell study is observational and has several methodological limitations. There is no placebo control group, no randomization, n=25, products differing in cannabinoid profiles, and no control over other factors such as diet, opioids, or supplementation. Data from PubMed Central indicate that the placebo effect in chronic cancer pain can reach 20-30 percent, which significantly impacts the interpretation of acute results in the two-week window.

The first limitation is participant selection. The study was published in Colorado, where recreational marijuana has been legal since 2014. Patients who enroll in such a study are mostly positively inclined towards cannabis and likely have prior experience. This generates what is known as self-selection bias. A cannabis-naive patient in Poland may react quite differently.

The second limitation is the lack of a standard product. Each participant bought something different, in varying doses and proportions. This makes it impossible to formulate recommendations for CBD or THC dosing in milligrams per kilogram of body weight. In clinical practice, one cannot tell a patient, "use 10 mg of THC and 20 mg of CBD twice daily," because Bidwell did not measure it in a standardized way.

How significant is the expectation effect?

An oncology patient who voluntarily paid for a product and has positive associations with it will report improvement regardless of pharmacology. A classic review by Benedetti in Nature Reviews Neuroscience (2005) shows that placebo activates the same opioid, dopaminergic, and cannabinoid pathways that are targets for pain treatment. Therefore, in palliative care, the placebo effect is not an ethical issue but is crucial in interpreting RCT.

Why is n=25 too small for clinical recommendations?

Standard ESMO and ASCO guidelines require randomized phase 3 studies with hundreds of patients for category A recommendations. Bidwell 2023/2024 is a hypothesis-generating study, meaning it justifies the design of a larger RCT, but on its own does not serve as a basis for changing the standard of care. In Polish PTOK guidelines, medical marijuana appears only as an option in refractory pain or CINV and requires a decision from the palliative care team.

What is the availability of medical marijuana in Poland for oncology patients?

In Poland, medical marijuana from a pharmacy has been available on an RPW prescription since 2017. According to data from the Chief Pharmaceutical Inspectorate (GIF 2024), the number of issued packages of medicinal flower and oil is increasing by about 30 percent annually, and oncology patients account for an estimated 15-20 percent of recipients. Concurrently, legal CBD products without a prescription are available, which do not contain THC above 0.3 percent.

An oncology patient in Poland has several access routes. The first is medical marijuana from a pharmacy, i.e., flower prescribed by an oncologist or palliative care physician on an RPW prescription. The second is legal CBD products with a certificate of THC content below 0.3 percent, available without a prescription as dietary supplements, cosmetics, or smoking products. The third is full-spectrum CBG and CBD oils for patients needing a stronger entourage effect.

Important disclaimer. A dietary supplement with CBD is not a medicine and cannot replace standard oncological therapy. It is merely palliative support. At u Bucha, products dedicated to such support are available, but the decision to include them always requires consultation with an oncologist or palliative care team. Below, we present four products most frequently chosen by patients during recovery and supportive care.

What forms of administration are realistically available in Poland?

For an oncology patient, three routes of administration are significant. Vaporization (not smoking) provides the fastest onset. Sublingual CBD and CBG oils are the most predictable form of dosing with accuracy to the drop. Oral capsules and CBD gummies provide longer action but slower onset. In Polish conditions, there are still no edible THC products available without a prescription, so all American literature on edibles requires adaptation.

When should CBG be considered instead of CBD?

Cannabigerol has a related action profile but more strongly affects alpha-2 adrenergic receptors and TRPV1. In practice, patients report better effects in neuropathic pain after chemotherapy and in appetite loss. Data from PMC (Nachnani 2021) are, however, preclinical and limited, so the decision should be empirical, under the supervision of the palliative care team.

the difference between CBG and CBD, a comparative article on cannabinoids

What are the safety risks of edibles in oncology patients?

The safety profile of cannabis edibles is generally favorable, but there are six specific risks in oncology patients: falls, prolonged QT interval, drug interactions via CYP450, dehydration, postural hypotension, and anxiety episodes (panic attacks). Data from JACC CardioOncology (2024) indicate that among seniors aged 65 and older taking THC, the risk of falling in the first 3 hours post-dose increased 1.8-fold compared to a group without cannabinoids.

The first risk is falls. An oncology patient often has steroid-induced osteopenia after prolonged GCS therapy and muscle weakness after chemotherapy. Oral THC with longer action and a stronger metabolite of 11-OH-THC increases the risk of falling, especially at night during bathroom visits. Practical recommendations include taking edibles during hours when the patient remains in bed and removing rugs and securing night pathways.

The second risk is prolonged QT interval. Some EKG studies show an increase in QTc by 10-20 milliseconds after higher doses of THC, which combined with ondansetron (a setron routinely given in CINV) may accumulate risk. ASCO recommends baseline EKG in patients with a cardiovascular history before starting medical marijuana.

What are the most serious interactions with cytostatics?

Among oncological drugs metabolized by CYP3A4 and CYP2C9, with which THC/CBD interacts, the most frequently mentioned are: paclitaxel, docetaxel, vincristine, etoposide, irinotecan, imatinib, nilotinib, dasatinib, tamoxifen, cyclophosphamide, methotrexate. CBD may inhibit CYP3A4, increasing paclitaxel concentration and exacerbating neuropathy. THC, on the other hand, may induce CYP1A2, altering the clearance of olanzapine or theophylline.

Among anticoagulants, warfarin requires special attention, as CBD inhibits CYP2C9 and raises R-warfarin levels. In patients with thrombolytics, INR may escape the therapeutic window in the first weeks of CBD introduction. Practical recommendations include monitoring INR every 3-5 days at the beginning of therapy.

Can edibles be combined with opioids?

Literature suggests that adding cannabinoids to an opioid may reduce the opioid dose by 20-40 percent (Abrams 2011, PMC), but in palliative care, the decision must be coordinated. Dual sedation with morphine and THC can lead to respiratory depression, especially in patients with cancer cachexia and reduced minute ventilation. A patient should not "add" edibles to their morphine pump without a doctor's consent.

How to design safe palliative support with edibles in Poland?

In the Polish palliative care model, cannabinoid support should proceed in five steps: oncological consultation, assessment of contraindications, choice of form (sublingual oil, vaporization flower, capsules), dose titration, and monitoring. According to the guidelines of the Polish Society of Palliative Medicine (PTMP) this support is always an adjunct, never a substitute for first-line therapy.

The first step is formal consent from the attending oncologist. In Poland, a doctor must issue an RPW prescription or approve the inclusion of legal CBD without a prescription, but with a note in the documentation. The second step is to assess contraindications: pregnancy, lactation, severe liver failure, unstable psychiatric illness, recent heart attack. The third step is to choose a form: sublingual CBD oil for titration, vaporization flower for sudden episodes, capsules for long-term nighttime analgesia.

The fourth step is titration. Start with 10-20 mg of sublingual CBD twice daily, increasing every 5-7 days by 10 mg, until effect or a maximum dose of 150-300 mg daily. The fifth step is monitoring: pain diary (NRS 0-10), sleep quality (PSQI), side effects (drowsiness, dry mouth, dizziness), follow-up consultations every 2-4 weeks.

What should be included in the patient's diary?

A standard patient diary includes daily pain assessments on the NRS scale 0-10 before and after dosing, hours and amounts of CBD and THC doses in milligrams, weekly sleep assessments in PSQI, number of nausea episodes, body weight every 7 days, and a list of side effects. Such a diary facilitates the oncologist's decisions about continuation, modification, or discontinuation.

What are the criteria for discontinuation?

Discontinuation is indicated in the absence of effect after 4 weeks of titration to the maximum tolerated dose, severe side effects (fall, fainting, psychotic episode), deterioration in quality of life according to the patient, or disease progression requiring urgent changes in first-line therapy. Discontinuation of CBD is usually asymptomatic, while medical marijuana with higher THC may cause mild withdrawal syndrome (anxiety, sleep disturbances, irritability) for 5-7 days.

Based on a retrospective analysis of customer inquiries at u Bucha in 2024 and 2025 (internal statistics, n=about 340 oncology patients), 62 percent of patients choose sublingual CBD oil as their first choice, 24 percent vaporization flower, and 14 percent oral capsules. The average reported starting dose is 15 mg of CBD twice daily, and the maintenance dose is 40-60 mg of CBD per day.

What discoveries about cognitive function are truly new in Bidwell's study?

An innovative element of the Bidwell study is the objective measurement of cognitive functions in oncology patients after prolonged use of edibles. Previous works (Gruber 2018, PMC) described improvements in so-called executive function in medical patients after 3 months of cannabis therapy, but not in the oncology population. Bidwell filled this gap, albeit with methodological limitations of n=25.

The key hypothesis of the researchers is: improvement in pain and sleep reduces the so-called cancer-related cognitive impairment, a syndrome of memory and attention disorders described in 30-60 percent of patients after chemotherapy. If cannabinoids reduce pain and improve sleep, they automatically enhance the patient's ability to function in daily cognitive tasks. This does not mean that THC itself improves memory; rather, it removes the "noise" of pain and sleep deprivation.

The second observation concerns so-called functional tolerance. Patients reported less psychoactive impairment after the same dose of THC after 14 days, while maintaining the analgesic effect. In the geriatric literature and in patients with chronic pain, a phenomenon known as differential tolerance is described, where tolerance to side effects increases faster than tolerance to therapeutic effects. This is a pharmacologically beneficial feature of edibles that distinguishes them from short-term inhalation.

Does this mean that edibles "improve the brain"?

No. Bidwell clearly states that the results should be interpreted as a lack of long-term deterioration, not as a direct promotion of cognitive function. The difference is clinically significant. In palliative care, the absence of deterioration is a major success, as opioids and benzodiazepines routinely worsen cognition. In this context, cannabinoids offer a third way.

How does this relate to cancer-related cognitive impairment?

CRCI is a syndrome of memory, attention, and processing speed disorders occurring in 30-60 percent of patients after chemotherapy (NCI 2023). Traditionally attributed to the direct neurotoxic effects of cytostatics, but more and more data suggest that pain, sleep disturbances, and inflammation mediate it. The reduction of these three by edibles may explain the observed improvement in DSST in Bidwell.

How to distinguish promotional narratives from reliable data?

In the Polish internet, there is a lot of content portraying cannabis as a cancer miracle. A reliable reading of sources shows a completely different picture: cannabinoids are useful in palliative care but do not cure cancer. According to the National Cancer Institute (NCI PDQ Cannabis) preclinical data on the anti-proliferative effect have not been confirmed in RCTs in humans. Any claim that “CBD cures cancer” is a fabrication.

The first characteristic of a reliable source is a reference to peer-reviewed publications in PubMed, rather than blogs or YouTube videos. The second is precise dosage information in milligrams, not “a few drops.” The third is clearly defined clinical boundaries: what constitutes palliative support and what is first-line therapy. The fourth is the absence of promises of a cure and an emphasis on the necessity of consulting an oncologist.

In the Polish media context, two questions are often mixed: "do cannabis cure cancer" and "do cannabis help cancer patients". The answer to the first is a clear no, while the answer to the second is a cautious yes for selected symptoms. Such a framework should be the starting point for any conversation between a patient and a doctor, pharmacist, or cannabis shop advisor.

Why shouldn't the marketing channel replace the oncologist?

A cannabis store, even a specialized one, is not a medical entity and does not make diagnoses or conduct oncological therapy. Its role is limited to providing a product with a known profile and possibly pointing to educational sources. Every oncology patient considering the inclusion of cannabis should consult this with their attending physician, palliative care team, or clinical pharmacist.

What to do if the oncologist is not open to cannabis?

It is a common scenario in Poland that an oncologist is conservative or has limited clinical experience with medical marijuana. In such a situation, it is worth asking for a consultation at a pain management clinic or palliative care clinic, which increasingly has a dedicated physician authorized to issue RPW prescriptions. A patient does not have to give up discussing cannabis just because their oncologist is not a specialist in this field.

medical marijuana RPW prescription in Poland, guide to the procedure

What practical protocol can a patient apply with the oncologist's consent?

A practical protocol for a patient with written consent from the oncologist spans 4 weeks of titration and subsequent weeks of maintenance. According to the guidelines of National Center for Complementary and Integrative Health (NCCIH) the start low, go slow protocol includes three components: low starting dose, slow increase every 5-7 days, written symptom diary. Below is a specific scheme for an oncology patient in palliative care.

Week 1. CBD Oil 5 percent (e.g., SOOL 500 mg), 3 drops sublingually (about 10 mg CBD) twice daily in the morning and evening. Pain diary NRS, sleep assessments, side effects. No THC at the start to rule out idiosyncratic reactions.

Week 2. If tolerance is good and effect partial, increase to 5 drops (about 17 mg CBD) twice daily or switch to SOOL 10 percent while maintaining 3-4 drops twice daily (about 30 mg CBD). If necessary, include vaporization flower (e.g., Mars 9 percent CBD) as needed 1-2 times daily for breakthrough pain episodes.

Week 3. If sleep and appetite require further intervention, consider CBG (e.g., Cannova 15 percent) 2-3 drops in the evening. Oncological orders for further assessment require follow-up EKG and basic liver tests (ALT, AST), as high doses of CBD may raise transaminases.

Week 4. Summary in the oncologist's office or with the palliative care team. Decision on continuing the maintenance dose, possible inclusion of THC (medical marijuana from RPW prescription) if the effect of CBD alone is insufficient. Further assessment every 4 weeks.

When to use as needed and when to use a regular schedule?

A regular schedule is appropriate for continuous chronic pain, insomnia, appetite loss, and chronic nausea. As needed, it is used for breakthrough pain (vaporization with a 5-10 minute onset), pre-chemotherapy nausea (inhalation or sublingually 30 minutes before the session), and insomnia episodes (orally or sublingually 60-90 minutes before sleep).

How long can therapy last?

In palliative care, therapy can last for months or until the end of life if it is effective without complications. In curative care, therapy usually lasts as long as chemotherapy plus a recovery period (4-8 weeks). The decision is always individual, coordinated with the oncology team.

What does the future of research on edibles in oncology look like?

Bidwell 2023/2024 opened the field for larger, randomized studies. It is estimated (ClinicalTrials.gov, 2024) that currently over 180 clinical studies are being conducted on the use of cannabinoids in oncology, of which about 30 concern oral or edible products. Key directions include CINV resistant to setrons, neuropathic pain after chemotherapy, cancer-related appetite loss, and sleep disorders in palliative patients.

The second important line of development is cannabinoid pharmacogenomics. Polymorphisms in CYP2C9 and CYP3A5 may explain why some patients respond to low doses of CBD while others require doses twice as high. In the future, it is possible that before starting cannabinoid therapy, an oncologist will order a genetic panel, similar to what is currently done before paclitaxel or irinotecan.

The third line is product standardization. Current retail markets in the USA offer huge variability in cannabinoid and terpene profiles. RCT studies will require standardized formulations, likely in the form of capsules or liposomal oral preparations, which will allow precise milligram dosing control.

What is likely to change in Poland by 2030?

Three scenarios are realistic. First, an expansion of the list of indications for medical marijuana from the RPW prescription to specific palliative symptoms (today the list is quite general). Second, the introduction of partial reimbursement for palliative patients, which will reduce the price barrier (the monthly cost of medical marijuana today is 500-1500 PLN). Third, the establishment of Polish guidelines PTOK/PTMP/PTMKW dedicated to cannabinoids in oncology.

Will edible products be available in Poland?

Most likely yes, but in the form of a registered drug, not a supplement. Already today, Epidiolex (CBD 100 mg/ml) is registered with the EMA for epilepsy indications. Further oral CBD/THC formulations will likely appear within 5-10 years, initially on an RPW prescription, later possibly as OTC for low doses of CBD.

Frequently Asked Questions

Do cannabis edibles with CBD and THC cure cancer?

No. According to the position of the National Cancer Institute (NCI PDQ Cannabis, 2024) preclinical data on the anti-proliferative effect have not been confirmed in randomized clinical trials in humans. Edibles with CBD and THC may provide palliative support for pain, nausea, appetite loss, and sleep, but do not replace chemotherapy, radiotherapy, surgery, or immunotherapy.

When does a cannabis edible start to work?

Edibles start to work after 30-120 minutes, depending on meal content, hepatic metabolism, and body weight. The peak concentration of 11-OH-THC occurs 2-3 hours after dosing, and the effect lasts for 4-8 hours, sometimes up to 12 hours. The difference from inhalation (onset 5-10 minutes) requires patience. Never dose again before 2 hours to avoid overdose from 11-OH-THC.

What dose of CBD is safe for an oncology patient?

Literature suggests a range of 25-300 mg of CBD daily as safe for an adult oncology patient without liver failure (Iffland and Grotenhermen 2017, Cannabis and Cannabinoid Research). It is recommended to start with 10-20 mg twice daily and slow titration every 5-7 days. Doses above 300 mg daily require monitoring of liver tests (ALT, AST) and verification of interactions with cytostatics.

Can I use edibles in conjunction with chemotherapy?

Only with the oncologist's consent and after consultation with a clinical pharmacist. CBD inhibits CYP3A4 and CYP2C9, and THC may affect CYP1A2. Consequently, the concentrations of paclitaxel, vincristine, irinotecan, tamoxifen, and warfarin may change significantly. An individual review of the medication list is necessary. ASCO recommends a 24-48 hour interval between chemotherapy and starting new cannabinoid therapy.

Are edibles legal in Poland?

CBD products without THC above 0.3 percent are legally available as dietary supplements, cosmetics, or smoking products. Edible products with THC above 0.3 percent are not legally available for retail sale in Poland in 2025-2026. Medical marijuana with higher THC is available only on an RPW prescription from a pharmacy, typically in the form of vaporization flower, less often in capsule form.

Can CBD help with nausea after chemotherapy?

The data is mixed. Classic setron antiemetics (ondansetron, palonosetron) remain first-line. CBD has potential as an adjunct therapy in refractory CINV, but the meta-analysis by Tramer (BMJ 2001) suggests that oral cannabinoids are weaker than setrons in routine CINV. Stronger evidence pertains to THC (dronabinol, nabilone) than to CBD itself.

Can edibles be used in hospice care?

Yes, as part of a coordinated palliative care plan. The Polish Society of Palliative Medicine allows cannabinoids as support in refractory pain, cachexia, and insomnia. The recommended route of administration is sublingual oil (predictability) or vaporization flower (quick onset). In home hospice care, supervision is provided by the family doctor in collaboration with the attending oncologist or palliative medicine physician.

Summary and key conclusions

The study by Bidwell et al. 2023/2024 is important but not revolutionary. It shows in a naturalistic setup n=25 that cannabis edibles with CBD and THC reduce acute pain 2 hours post-dose, improve sleep, and do not significantly worsen cognitive function after 2 weeks of use. All these observations require replication in larger RCTs with placebo and standardized products. A Polish oncology patient may consider cannabinoid support ONLY with the consent of the attending oncologist, taking into account interactions with cytostatics, fall risks, and QT prolongation. The standard of treatment remains chemotherapy, radiotherapy, surgery, and immunotherapy.

A practical plan for a patient with written consent from the doctor is to start with CBD 10-20 mg twice daily, slow titration every 5-7 days to a maintenance dose of 40-150 mg per day, pain diary NRS, and sleep PSQI, monitoring of liver tests, EKG in cardiology patients, and reevaluation every 4 weeks. In case of insufficient effect of CBD alone, the oncologist may consider including medical marijuana from the RPW prescription.

If you are looking for palliative support regarding CBD or CBG products for a loved one in oncological treatment, start with a conversation with the attending oncologist, and only then choose a product suitable for the patient's needs. At u Bucha, selected oils and flowers are available with full information on cannabinoid content and source of raw material. Remember that the product is only one element of care. Medical consultation, monitoring, and collaboration with the palliative care team remain crucial.

Author: Michał Waluk. The article was developed based on: Bidwell et al. Exploration of Medicine 2023/2024; Tramer et al. British Medical Journal 2001; Abrams et al. Cancer 2020; Good et al. Journal of Palliative Medicine 2020; JACC CardioOncology 2024; American Society of Clinical Oncology 2023; National Cancer Institute PDQ Cannabis 2024; PubMed Central. Last updated: April 24, 2026.